Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPG.0000000000000503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment of Refractory Ulcerative Colitis With 5-Aminosalicylic Acid Intolerance and Biologic Therapy Resistance Using Combined Granulocyte and Monocyte Adsorptive Apheresis.
Cureus
January 2025
Department of Gastroenterology, Tsuchiya General Hospital, Hiroshima, JPN.
We report the case of a 37-year-old male patient diagnosed with moderate left-sided ulcerative colitis (UC). Initial therapy with 5-aminosalicylic acid (5-ASA) was terminated within days due to exacerbation of symptoms, leading to a diagnosis of 5-ASA intolerance. Although induction of remission was achieved with prednisolone, the patient developed steroid dependency.
View Article and Find Full Text PDFEmerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris.
Life (Basel)
July 2024
Section of Dermatology-Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy.
Article Synopsis
- Pityriasis rubra pilaris (PRP) is a rare skin disease that causes red and scaly patches, making it hard to treat.
- Because PRP is uncommon and can sometimes get better on its own, studying how to treat it is tricky.
- New medicines that target specific parts of the immune system, like IL-17 and IL-23, have shown some promise for treating PRP, but more research is needed to understand how well they work.
Biologic therapy for ulcerative colitis associated with immune thrombocytopenia.
Clin J Gastroenterol
October 2024
Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Article Synopsis
- Ulcerative colitis (UC) can sometimes lead to issues outside the intestines, such as immune thrombocytopenia (ITP), a condition where platelet levels drop.
- A 51-year-old man with severe UC and ITP did not respond to standard treatments, but treatment with biologic drugs like ustekinumab and adalimumab helped him achieve remission in both conditions.
- This case highlights how effective biologics can be in treating difficult UC cases accompanied by ITP, suggesting they might help avoid the need for surgery.
Ustekinumab effectiveness in Crohn's disease with lesions in the intestines.
Medicine (Baltimore)
April 2024
First Department of Medicine, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Japan.
Article Synopsis
- * While the overall improvement in Crohn's disease activity was not significant after 48 weeks, patients with only small intestine lesions showed notable progress in their condition and improved albumin levels.
- * Treatment retention rates were high for both groups, indicating ustekinumab is a safe and effective option, particularly for those with small intestinal lesions.
Erythromelalgia Secondary to Anti-Tumor Necrosis Factor (TNF) Alpha Therapy: A Report of Two Cases.
Cureus
February 2024
Department of Gastroenterology and Hepatology, Ibn Rochd University Hospital Center, Casablanca, MAR.
Erythromelalgia is a rare syndrome with a generally unknown etiology. Whether primary or secondary, this condition is characterized by paroxysmal episodes of erythema, pain, and heat in the extremities. We report two cases of erythromelalgia occurring after the initiation of treatment with infliximab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!